Mycophenolatmofetil Biomo (Mycophenolate Mofetil)

Mycophenolate Mofetil inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for de novo synthesis of guanosine nucleotides. Lymphocytes rely heavily on this pathway, so inhibition reduces their proliferation and dampens both cellular and humoral immune responses, helping to prevent graft rejection and control autoimmunity.

The prescribed dose of Mycophenolatmofetil Biomo is set by the treating physician based on the specific indication, patient weight, renal and hepatic function, and any concomitant medications. Dosing regimens vary between transplant prophylaxis and autoimmune disease management, and adjustments may be required over time.

Mycophenolate Mofetil is classified as Pregnancy Category X because it is teratogenic and can cause fetal malformations. It is contraindicated during pregnancy and should be stopped well before conception. Breastfeeding is also not recommended, as the drug is excreted in milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and the necessary import documentation.

Compared with azathioprine, another antimetabolite, mycophenolate offers more selective inhibition of lymphocyte proliferation and generally a lower incidence of certain toxicities, but both can cause bone‑marrow suppression. Compared with calcineurin inhibitors (e.g., cyclosporine), mycophenolate has a different side‑effect profile, lacking nephrotoxicity but requiring monitoring for gastrointestinal and hematologic effects.

Mycophenolatmofetil Biomo should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity to maintain potency.

The medication is taken orally, usually as whole tablets or capsules. It can be taken with or without food, but consistent intake with respect to meals helps maintain stable absorption. Patients should swallow the dose whole and not crush or chew the tablets unless specifically instructed by a healthcare professional.

Serious risks include bone‑marrow suppression leading to leukopenia or anemia, severe opportunistic infections such as Pneumocystis jirovecii pneumonia, hepatic dysfunction, and teratogenic effects if pregnancy occurs. Patients should report signs of infection, unusual bruising, jaundice, or any pregnancy‑related concerns immediately to their clinician.

Mycophenolatmofetil Biomo is contraindicated in pregnant women, individuals with known hypersensitivity to mycophenolate or its excipients, patients with uncontrolled active infections, and those with severe renal impairment unless dose‑adjusted under specialist supervision. Caution is also advised for patients with significant hepatic disease.